1. Borcherding DC, Hugo ER, Idelman G, Richtand NW, Loftus J, et al. Dopamine receptors in human adipocytes: expression and functions. PLoS One 2011;6:e25537.

2. Borcherding DC, Tong W, Hugo ER, Barnard DF, Fox S, et al. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene 2016;35:3103-13.

3. Amenta F, Ricci A, Tayebati SK, Zaccheo D. The peripheral dopaminergic system: morphological analysis, functional and clinical applications. Ital J Anat Embryol 2002;107:145-67.

4. Laidler P, Kowalski D, Silberring J. Arylsulfatase A in serum from patients with cancer of various organs. Clin Chim Acta 1991;204:69-77.

5. Chung KY. Structural aspects of GPCR-G protein coupling. Toxicol Res 2013;29:149-55.

6. Sprang SR. Invited review: activation of G proteins by GTP and the mechanism of Galpha-catalyzed GTP hydrolysis. Biopolymers 2016;105:449-62.

7. Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. Proc Natl Acad Sci USA 1972;69:2145-9.

8. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63:182-217.

9. Rubi B, Maechler P. Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance. Endocrinology 2010;151:5570-81.

10. Reis HJ, Rosa DV, Guimaraes MM, Souza BR, Barros AG, et al. Is DARPP-32 a potential therapeutic target? Expert Opin Ther Targets 2007;11:1649-61.

11. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004;24:165-205.

12. Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015;172:1-23.

13. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001;345:1548-57.

14. Windham PF, Tinsley HN. cGMP signaling as a target for the prevention and treatment of breast cancer. Semin Cancer Biol 2015;31C:106-10.

15. Pyriochou A, Papapetropoulos A. Soluble guanylyl cyclase: more secrets revealed. Cell Signal 2005;17:407-13.

16. Sharma RK, Duda T. Membrane guanylate cyclase, a multimodal transduction machine: history, present, and future directions. Front Mol Neurosci 2014;7:56.

17. Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195-233.

18. Courtis F, Carrier S, Charvier K, Guertin PA, Journel NM. The control of male sexual responses. Current Pharm Des 2013;19:4341-56.

19. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 2009;15:3464-75.

20. Wolfertstetter S, Huettner JP, Schlossmann J. cGMP-dependent protein kinase inhibitors in health and disease. Pharmaceuticals (Basel) 2013;6:269-86.

21. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, et al. Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist 2016;21:869-74.

22. Ligresti G, Libra M, Militello L, Clementi S, Donia M, et al. Breast cancer: molecular basis and therapeutic strategies (Review). Mol Med Rep 2008;1:451-8.

23. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008;34:378-90.

24. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem 2015;7:1511-9.

25. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010;316:1083-100.

26. Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med 2019;17:90.

27. Carlo RD, Muccioli G, Bellussi G, Portaleoni P, Ghi P, et al. Steroid, prolactin, and dopamine receptors in normal and pathologic breast tissue. Ann N Y Acad Sci 1986;464:559-62.

28. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012;149:1284-97.

29. Minami K, Liu S, Liu Y, Chen A, Wan Q, et al. Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis. Sci Rep 2017;7:45686.

30. Yang L, Yao Y, Yong L, Feng Y, Su H, et al. Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness. Eur J Pharmacol 2019;859:172499.

31. Zhao DL, Zou LB, Lin S, Shi JG, Zhu HB. Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line. Neuropharmacology 2007;53:724-32.

32. Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, et al. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 2011;17:3649-59.

33. Chiarenza A, Scarselli M, Novi F, Lempereur L, Bernardini R, et al. Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. Eur J Pharmacol 2001;433:47-54.

34. Johnson DE, Ochieng J, Evans SL. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs 1995;6:471-4.

35. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res 2009;69:3727-30.

36. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, et al. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 2004;287:H1554-60.

37. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-6.

38. Chumpradit S, Kung MP, Billings JJ, Kung HF. Synthesis and resolution of (+-)-7-chloro-8-hydroxy-1-(3’-iodophenyl)-3-methyl-2,3,4,5-tetrahydro- 1H-3- benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor. J Med Chem 1991;34:877-83.

39. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-78.

40. Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J 2011;278:3360-9.

41. Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, et al. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010;124:349-60.

42. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, et al. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 2011;4:1275-84.

43. Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling. Mol Cancer Ther 2013;12:1848-59.

44. Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 2006;240:60-8.

45. Shi Z, Tiwari AK, Patel AS, Fu LW, Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res 2011;71:3735-8.

46. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 2010;107:18202-7.

47. Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, et al. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther 2014;15:758-67.

48. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol 2014;85:408-19.

49. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 2015;147C:12-21.

50. Kitamura K, Singer WD, Star RA, Muallem S, Miller RT. Induction of inducible nitric-oxide synthase by the heterotrimeric G protein Galpha13. J Biol Chem 1996;271:7412-5.

51. Kim SG, Lee CH. G-protein signaling in iNOS gene expression. Methods Enzymol 2005;396:377-87.

52. Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:30-8.

53. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702.

54. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008;49 Suppl 2:149S-63.

55. Reddy S, Robinson MK. Immuno-positron emission tomography in cancer models. Semin Nucl Med 2010;40:182-9.

56. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010;14:1-103.

57. Charpentier S, Jarvie KR, Severynse DM, Caron MG, Tiberi M. Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties. J Biol Chem 1996;271:28071-6.

58. Plouffe B, D’Aoust JP, Laquerre V, Liang B, Tiberi M. Probing the constitutive activity among dopamine D1 and D5 receptors and their mutants. Methods Enzymol 2010;484:295-328.

59. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res 1996;51:319-51.

60. Black LE, Smyk-Randall EM, Sibley DR. Cyclic AMP-mediated desensitization of D1 dopamine receptor-coupled adenylyl cyclase in NS20Y neuroblastoma cells. Mol Cell Neurosci 1994;5:567-75.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: